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INTRODUCTION
Medicare beneficiaries enrolling in the new prescription drug
coverage plans found that along with the financial relief came a
dizzying array of choices inequities that result in very different
coverage options and prices depending on where they live. This
does not have to be the case. Taxpayers who foot 75% of the bill
deserve the benefit of leveraging of public purchasing power.
Medicare beneficiaries deserve a prescription drug option they
can understand, that is uniform nationwide, that meets
unexpected needs, and that achieves deep drug discounts.
MARKETPLACE CONFUSION
The choices a typical senior faces are many: a stand-alone plan
or drug coverage through a Medicare advantage plan; copay-
ment level and tier structure; deductible; formulary (which
drugs are covered and the basis for selection); restrictions
such as prior authorization; gaps in coverage, and many more.
As the paper, “Variation in Estimated Medicare Prescription
Drug Plan Costs and Affordability for Beneficiaries Living in
Different States,” by Davis et al. shows, the premiums that
beneficiaries face for identical overage can vary widely by state
—building in a new level of unfairness in Medicare, designed
originally with a uniform benefit for which the key eligibility
criteria was reaching age 65.
Confusion in the marketplace can set the stage for fraud
and abuse, the kind that occurred in the 1970s and 1980s
when insurance agents exploited the fears of vulnerable
seniors by selling them duplicative, overlapping policies to
cover the gaps in Medicare. Too much choice can be counter-
productive and overwhelming
1. Medicare beneficiaries—espe-
cially those with impaired vision or no web-surfing experience
—need a more rational marketplace, a simplified choice, and a
seller they can trust.
A surplus of choice and confusion in the marketplace is a
sign of breakdown of marketplace competition
2. If Medicare
beneficiaries were choosing the plans with the lowest costs and
highest quality, then overpriced poorer quality plans should be
forced out of the market. The proliferation of new plans and
more choices for 2007, compared with 2006, combined with
the failure of the government to provide useful comparative
quality information, suggests that despite the existence of a
powerful plan finder cost comparison tool, the forces of
competition have not yet gone to work on behalf of Medicare
beneficiaries.
An ideally functioning marketplace, though, will still not
help everyone because one cannot predict getting cancer or a
stroke and so fails to pick a plan that is “good” for that future
disaster. Variations in benefit design result in a wide range of
cost-sharing, with the percent difference between the lowest
and highest cost Part D plans ranging from 47% (for metastatic
breast cancer) to 2,740% (for metastatic colon cancer)
3. How
long can the nation’s seniors and the disabled wait until the
full benefits of a healthy competitive marketplace are
achieved? How can cancer patients and others unable to
predict future drug needs be protected against high out-of-
pocket costs?
The 1990 OBRA reforms of the medigap marketplace
showed that sound public policy—in that case simplification
of a complex market through standardizing the benefit
packages—can help this vulnerable population get better value
for their health insurance dollar
4, 5. Congress should apply
lessons from the medigap marketplace to the prescription drug
marketplace, and provide seniors and the disabled with a
uniform drug benefit that is easily understood, can be trusted,
and can improve on coverage by putting the negotiating power
of the federal government to work on behalf of this population.
GEOGRAPHIC INEQUITIES
The analysis by Davis et al. shows a high level of variation in
prices for prescription drug plans: a patient (with serious
chronic conditions) shopping for the lowest-priced plan in
Florida will pay over $12,000 more than the patient with
identical drug needs) in Georgia. This newly introduced
inequity is another in a series of steps that erodes the original
design of the Medicare program, which was conceived as a
program to provide uniform hospital and doctor coverage
regardless of geography.
This is not the first time Congress created geographical
inequities. The introduction of Medicare HMOs in the 1980s
led to a departure from the nationwide uniform Medicare
benefit and resulted in widely differing coverage in different
parts of the country. The gradual introduction of private HMO
coverage has both complicated the choices beneficiaries must
make and introduced major variation because the coverage
varies based on where you live.
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286Whereas beneficiaries welcome expanded coverage, it has
come at a high price in terms of fairness and government
subsidization of private companies. The benefits that were
sweetened recently by the Medicare Modernization Act (MMA)
are the result of generous taxpayer-provided subsidies that
mean that it costs Medicare more, not less, when a beneficiary
enrolls in a private (vs. the traditional) Medicare plan. The cost
of the extra payments (in excess of average fee-for-service
costs) to Medicare Advantage plans is estimated to be $30
billion over the 5-year period between 2007 and 2011
6.
Supporters of privatization, though, promote the myth that
the private companies are the key to constraining costs. The
Minnesota Senior Federation has shown the local impact of
this misguided policy: in a study of the market just before the
MMA, seniors in Minnesota would have to pay almost $300 a
month to get “extra” Medicare benefits that included pre-
scription drugs, dental, vision, and hearing services that were
free to seniors in parts of Florida, New York, and some other
states
7. Dr. John Wennberg and his colleagues have found
Medicare costs (after adjusting for health status) are twice as
high (or more) in some regions compared to others
8. Medicare
can address this inequity by restoring uniform benefits, start-
ing with a uniform drug benefit option.
SMALL DRUG DISCOUNTS
Another disappointment is the new drug benefit’s failure to
attain large discounts on the prices paid. The 40 to 60
insurance companies (in each state) that create preferred drug
lists and negotiate drug prices with pharmaceutical companies
do not achieve the deep discounts that can be attained by
putting the purchasing power of the federal government (or
groups of states) to work. A Consumers Union study of drug
prices in Broward County, Florida found that Medicare Part D
drug prices are between 10 and 20% lower than prices
available at retail drug stores. In contrast, the Department of
Veterans Affairs negotiates discounts that are over 50% off
retail prices
9. States with evidence-based preferred drug lists
and effective drug bidding processes have also achieved
substantial savings for their Medicaid drug purchases. In
Medicare Part D, premiums paid by beneficiaries cover 25%
of the cost of the drug benefit; taxpayers are footing the bill for
the other 75% and are paying the most of the cost of this
failure to rein in drug costs.
States have also shown leadership in curbing prescription
drug spending, while assuring Medicaid enrollees have access
to the most effective, safe, and affordable medicines. A key
ingredient in their success, and the VA’s success with its drug
formulary, is basing preferred drug lists on reports that show
the comparative clinical effectiveness of drugs, and balance the
need for flexibility with the goal of cost containment. The
Oregon Health & Science University–based Drug Effectiveness
Review Project (DERP), now used by 15 states to help guide
drug selection for their Medicaid programs, has developed a
valuable database of systematic reviews, providing U.S. lead-
ership for putting evidence-based medicine into practice by
policymakers
10. States are free to take local preferences with
regard to restrictiveness of formulary versus cost containment
in making use of such a database to achieve substantial
savings
11. Medicare beneficiaries and physicians can learn
more about DERP findings through Consumer Reports Best
Buy Drugs
12, which translates the complex systematic reviews
for the public, and provides information for free in English and
Spanish for 16 categories of drugs including commonly used
drugs for high blood pressure, high cholesterol, depression,
allergies, and insomnia. Reliance of DERP-based Best Buy
Drugs recommendations can help beneficiaries save thousands
of dollars a year, in many cases helping them avoid the feared
Medicare “doughnut hole” gap in coverage
13.
CONGRESS SHOULD FIX THE MEDICARE
MODERNIZATION ACT
Congress should act promptly to address the confusion and
inequities in the Medicare drug program and provide benefi-
ciaries with a drug coverage option that is uniform nationwide,
creates a formulary based on evidence, negotiates deep
discounts, and uses the savings to create a more rational
benefit design that eliminates the “doughnut hole.”
Medicare coverage should be uniform nationwide, with the
drugs on the formulary selected because they are the most
effective and safe, with minimal side effects. An evidence-based
preferred drug list, paired with negotiation of deep discounts,
would allow coverage (of drugs on the PDL) during the
doughnut hole. An effective exceptions and appeals process
would be available to those who need to go off formulary.
Medicare beneficiaries deserve a prescription drug option that
they can understand, that is uniform nationwide, with a
rational benefit structure that provides fair coverage when
unexpected needs arise, and with discounts that bring down
t h ec o s to nb e h a l fo ft h o s ep a y i n gt h ep r e m i u m sa n d
taxpayers. Congress should make fixing the flawed Medicare
law a top priority in 2007.
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